Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeyondSpring Approved for China Arm of Global Phase III Cancer Trial

publication date: Dec 22, 2015
BeyondSpring Pharma, a New York City virtual immuno-oncology cancer company, received China approval to conduct a Phase III trial of its lead drug, plinabulin. The China arm will be part of a global trial that expects enroll 550 subjects in the US, China, Australia and New Zealand. Plinabulin, which has an anti-angiogenesis mechanism, will be administered in combination with docetaxel in patients who have non-small cell lung cancer (NSCLC). Approval for the US arm of the trial was granted in July 2015. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital